The introduction of inhaled corticosteroids (ICS) proved to be a turning point in the management of asthma, and they remain the cornerstone of asthma treatment today.1,2 However, during the 1990s in the UK and Europe, there was a trend towards use of higher doses and this, coupled with the introduction of more potent ICS products, resulted in many people with asthma being prescribed high-dose ICS therapy, even though evidence of significant additional clinical benefit from this approach was limited.1 Although it was common for patients to be ‘stepped up’ to higher doses of ICS in line with national …